REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [31] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [32] Final results of a randomized phase III trial comparing irinotecan plus oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines
    Haller, Daniel G.
    Rothenberg, Mace L.
    Wong, Alfred O.
    Koralewski, Piotr M.
    Miller, Wilson H., Jr.
    Bodoky, Gyorgy
    Olivatto, Luis O.
    Burger, Brent G.
    Kearney, Jill G.
    Garay, Carlos A.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [33] PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN (TIROX) IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Hong, Y. S.
    Kim, S. Y.
    Park, J. W.
    Lim, S.
    Choi, H. S.
    Jeong, S. Y.
    Kim, D. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [34] A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
    Taira, Koichi
    Yoshida, Motoki
    Sugimoto, Naotoshi
    Kii, Takayuki
    Kuwakado, Shin
    Fukunaga, Mutsumi
    Hasegawa, Hiroko
    Kato, Takeshi
    Miyake, Yasuhiro
    Hata, Taishi
    Tokunaga, Yukihiko
    Takeda, Koji
    Daga, Haruko
    Yoshinami, Tetsuhiro
    Shimokawa, Toshio
    Sakai, Daisuke
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
    Zhao, Xiao-Yin
    Liu, Xin
    Li, Wen-Hua
    Qiu, Li-Xin
    Huang, Ming-Zhu
    Wang, Chen-Chen
    Chen, Zhi-Yu
    Zhang, Wen
    Feng, Wan-Jing
    Guo, Wei-Jian
    Zhu, Xiaodong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Farr, Katherina Podlekareva
    Vestermark, Lene Weber
    Jensen, Helle Anita
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study - Trial in progress
    Kawaguchi, K.
    Nishitai, R.
    Manaka, D.
    Ota, T.
    Nishikawa, Y.
    Kudo, R.
    An, H.
    Hamasu, S.
    Konishi, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Kim, Sun Young
    Hong, Yong Sang
    Kim, Byung Chang
    Park, Ji Won
    Choi, Hyo Seong
    Jeong, Seung-Yong
    Kim, Dae Yong
    Hong, Chang Won
    Sohn, Dae Kyung
    Jung, Kyung Hae
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 269 - 274
  • [39] A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Sun Young Kim
    Yong Sang Hong
    Byung Chang Kim
    Ji Won Park
    Hyo Seong Choi
    Seung-Yong Jeong
    Dae Yong Kim
    Chang Won Hong
    Dae Kyung Sohn
    Kyung Hae Jung
    Investigational New Drugs, 2009, 27 : 269 - 274
  • [40] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
12345